LIH Researchers Uncover Key Immunity Differences Between Mild, Severe COVID-19

Using state-of-the-art deep immune profiling and systems immunology-driven data analysis, the translational biomedical research team, led by the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH), revealed that it is the unique combination of various early-stage immune responses that can differentiate between mild patients, hospitalised COVID-19 patients and their non-infected household controls.

From the beginning of the COVID-19 pandemic, the majority of research studies focused on severe COVID-19 patients in order to understand the causes of critical illness. However, it is equally important to understand the protective immune factors in our body and why some people have mild or no symptoms.

COVID-19 had varied effects worldwide, leading to an unprecedented diversification and intensification in research efforts to understand and limit its spread. However, while immunopathology has been widely studied in severe COVID-19 patients, immune responses in non-hospitalised patients have remained largely elusive. Furthermore, research to date has lacked a comprehensive multi-faceted approach to the full immune response following infection. It was therefore unknown, up to now, whether the immune alterations present in hospitalised individuals were also present in mild COVID-19 PCR-positive patients. To this end, Prof Dr Markus Ollert and Dr Feng Q. Hefeng, led a study to reveal the early-stage immune features of patients who had recently contracted the virus but displayed mild COVID-19 symptoms only.

The all-Luxembourg study took advantage of the translational medicine research structure established across the Grand Duchy. The translational study was based on the cohort Predicting the severity of COVID-19 infection (Predi-COVID), which was initiated in April 2020 to identify important risk factors and biomarkers associated with COVID-19 severity in Luxembourg.

Guy Fagherazzi, Director of the Department of Precision Health, and one of the two Principle Investigators (PI) of the Predi-COVID project, acknowledged : “Our work was only possible thanks to the unique opportunity to conduct a population-wide PCR screening in Luxembourg from May 2020 onwards that allowed us to recruit many SARS-CoV-2-infected people with only mild or no symptoms”.

Since its launch in April 2020, the study has collected data from COVID-19 positive adults in Luxembourg and followed their health conditions during the first three weeks after their diagnosis and beyond.

To obtain a comprehensive picture of the early-stage immune responses in COVID-19 infection, patients were categorised according to their symptoms’ severity (asymptomatic, mild, and hospitalised). By comparing immune responses between the different groups in more than 100 patients and household control individuals, the team found that, within three days following the positive PCR test, there was an early-stage increase in coordinated immune responses only in patients with mild symptoms. Key immune mediators like interferon beta and interferon gamma-induced protein 10 (IP-10) temporarily increased early-on according to the amount of virus present in the body of mild patients. After three weeks, these immune markers remained high in hospitalised patients, but decreased to normal values in mild patients. The early increase of crucial biomarkers in mild patients was accompanied by a rise in immune cells reacting specifically to the SARS-CoV-2 virus like CD4+ T cells, which are part of the adaptive arm of the immune system and of early-reacting innate immune cells, such as antigen-presenting cells and monocytes.

These early immune reactions anticipated the presence of specific antiviral antibodies three weeks later in mild patients, a feature that was absent in hospitalised patients. While hospitalised COVID-19 patients mounted an equally strong T cell response as mild patients, the frequency of innate immune cells and the expression of key functional molecules on these cells were strikingly impaired already very early on during infection in hospitalised patients. According to Christophe M. Capelle, first author of the study, turning on multiple immune functions in parallel and very early on in a coordinated fashion appears to be a major contributor to the beneficial clinical outcome of patients with mild symptoms.

Dr Hefeng commented: "These pioneering findings are the perfect example of the tremendous translational potential of ourresearch infrastructure in Luxembourg”. He continued “The longitudinal Predi-COVID study gave us unique access to PCR-positive mild non-hospitalised COVID-19 patients, to gain a comprehensive picture of distinct early-stage protective immune signatures in mild COVID-19 patients versus hospitalised patients, asymptomatic individuals and household controls during thefirst waves of the pandemic”.

Prof Ollert added: “Our work provides a rich data and clinical sample resource based on the unique opportunity to fully explore and understand all essential facets of the early-stage and dynamic immunological changes following recent SARS-CoV-2 infection in mild COVID-19 patients, using an unbiased, combinatorial and prospective approach”. He underscored: “Our current study not only provide information on the number and frequency of a wide spectrum of immune cells helping to defend against viruses like SARS-CoV-2 in our blood, but also on the functional status and characteristics of individual immune cell types”.

These first research results of the Predi-COVID study were recently published in the leading biomedical journal Cell Reports Medicine, titled ‘Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients’.

Predi-COVID will continue from 2022 onwards under the umbrella of CoVaLux (COVID-19, Vaccination & long-term health consequences of COVID-19 in Luxembourg), a national research effort coordinated by Research Luxembourg to address key unanswered questions related to COVID-19, with a particular focus on vaccination efficacy and the longer-term health impact of COVID-19.